Loading
Life sciences · Journal article
Expert Opinion on Pharmacotherapy · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
INTRODUCTION: Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis (MASLD/MASH) pharmacotherapy is changing rapidly after the approval of resmetirom and semaglutide for selected adults with noncirrhotic MASH and F2-F3 fibrosis; management must also address obesity, type 2 diabetes, dyslipidemia, cardiovascular risk, and kidney disease. AREAS COVERED: This structured narrative review evaluates approved, comorbidity-directed, repurposed, and emerging therapies according to mechanism, regulatory status, endpoint strength, safety, interactions, and implementation. PubMed and ClinicalTrials.gov were searched without a lower date limit through September 2026 and supplemented by U.S. and European regulatory documents, society guidance, randomized trials, systematic reviews, meta-analyses, and selected mechanistic studies. Therapies include thyroid hormone receptor-beta agonism, incretin and glucagon-containing agonists, peroxisome proliferator-activated receptor pathways, sodium-glucose cotransporter 2 inhibition, de novo lipogenesis/fatty acid synthase inhibition, fibroblast growth factor 21 analogues, lipid/remnant pharmacology, farnesoid X receptor signaling, antioxidants, and lower-evidence repurposing candidates. EXPERT OPINION: Resmetirom and semaglutide anchor approved MASH-directed treatment in eligible F2-F3 disease, while comorbidity-directed therapy should be individualized by liver stage and cardiometabolic priorities. Tirzepatide, FGF21 analogues, denifanstat, and rational combinations may broaden treatment, but cross-trial comparisons and surrogate endpoints require cautious interpretation.